PSP/reg Biomarker Severity Score for SARS Triage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for assessing the severity of SARS-CoV-2 infections, particularly in ICU settings, are cumbersome and lack predictive accuracy for early identification of septic shock and multiple organ dysfunction, leading to delayed patient management and high mortality rates.
Innovation Solution
A severity score composed of a respiratory system score and a pancreatic stone protein/regenerating protein (PSP/reg) score, determined from a body fluid sample, is used to quickly assess the severity of SARS-CoV-2 infections, allowing for timely triage and treatment prioritization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If the SOFA score is used to assess severity, then comprehensive organ dysfunction evaluation is achieved, but the assessment becomes cumbersome and delayed due to multiple parameters and central laboratory requirements
Solution Approach 1:
The patent extracts the essential diagnostic function from the complex SOFA score by identifying and isolating PSP/reg as a single key biomarker that captures the critical information about organ dysfunction and sepsis risk, eliminating the need for multiple parameter measurements and central laboratory processing
Solution Approach 2:
PSP/reg serves as an intermediary biomarker that mediates between the complex physiological state of organ dysfunction and the simplified assessment need, providing a single measurable parameter that reflects the underlying pathophysiology without requiring direct measurement of multiple organ systems
2Reliability
If multiple clinical signs and SOFA score are combined for diagnosis, then diagnostic comprehensiveness is improved, but diagnostic simplicity and speed are lost
Solution Approach 1:
The patent extracts the diagnostic essence from multiple clinical signs and SOFA score by identifying PSP/reg as the single most informative biomarker that captures the critical diagnostic information needed for sepsis and organ dysfunction assessment, simplifying the diagnostic process while maintaining reliability
Solution Approach 2:
The patent segments the complex diagnostic process into two distinct components: a simple clinical assessment part and a laboratory biomarker part (PSP/reg), allowing each to be optimized independently while maintaining overall diagnostic comprehensiveness
3Reliability
If existing biomarkers like Procalcitonin and CRP are used, then diagnostic capability is provided, but early detection accuracy and speed are insufficient
Solution Approach 1:
The patent changes the diagnostic parameter from traditional biomarkers like Procalcitonin and CRP to PSP/reg, which exhibits different temporal and quantitative characteristics that enable earlier and more accurate detection of sepsis and organ dysfunction, particularly in SARS-CoV-2 infected patients
4Reliability
If comprehensive patient monitoring is implemented, then patient management quality is improved, but resource burden on ICU increases
Solution Approach 1:
The patent extracts the essential monitoring function by focusing on PSP/reg as a single biomarker that provides the critical information needed for patient management decisions, reducing the resource burden of comprehensive monitoring while maintaining the ability to identify patients at risk of deterioration
Data Source
AI summary
The present invention relates to a method for assessing the severity of Severe Acute Respiratory Syndrome (SARS) in a patient; said method being based on a severity score consisting of at least: a) a respiratory system score, b) a score determined by the level of pancreatic stone protein/regenerating protein (PSP/reg) in a body fluid sample from said patient. The invention may be used in a healthcare unit for sorting patients to decide the treatment priority